From: Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
Strategy
Cost
Incremental Cost
Un adjusted Life-years
Incremental LYs
QALYs
Incremental QALYs
ICER ($/QALY)
SSA
$606,397
$170,455
4.41
0.62a
2.90
0.44
$388,966
Delay SSA
$435,942
–
3.78
2.46